Healthcare / Biotech
Editas Medicine
30-Second Executive Brief
Executive Assessment
Editas Medicine functions as a regional institution within Healthcare / Biotech, backed by 0% sourcing coverage, with accelerating strategic relevance.
- Maintains 2 mapped relationships across the graph
- 0% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare / Biotech category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 0%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
CRISPR gene editing biotechnology company. Editas Medicine announced second-quarter 2026 results and business updates on its in vivo gene editing pipeline.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions Bristol Myers Squibb
“The increase was primarily attributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additional research programs under its collaboration with BMS.”
SEC 8-K exhibit (0001650664-26-000082) · Aug 5, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- BioSpace — Editas Medicine announces Q2 2026 results and business updatescompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Editas Medicine — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
Editas Medicine's Timeline
A sourced, dated history of Editas Medicine's key moments — founding to present.
Aug 2026 · Reports Q2 2026 results and business updates
Editas Medicine announced second-quarter 2026 results and business updates on its gene editing pipeline.